Alpha-2 adrenergic agonists for the prevention of cardiac complications among patients undergoing cardiac surgery
A Cochrane review 1 included 47 studies with a total of 17,039 subjects. 24 trials (n=2672) included participants undergoing cardiac surgery. Overall, α-2 adrenergic (clonidine, dexmedetomidine, or mivazerol) agonists appeared to have no effect on the risk of mortality or myocardial infarction, but they appeared to increase the risk of bradycardia when compared to placebo. The quality of evidence was inadequate to draw conclusions regarding the effects of α-2 agonists on stroke or hypotension during cardiac surgery.
SOF table (licence required) https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004126.pub3/fu...
Comment: The quality of evidence is downgraded by imprecise results (wide confidence intervals).
Copyright © 2022 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.